- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01908907
Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants
The purpose of this study is to understand if the "DHA gap" can be corrected by giving a daily dose of DHA oil to preterm babies.
DHA is an essential omega-3 fatty acid, which means our body cannot make DHA. We have to take it in through our diet. DHA is important for normal brain and eye health and it may also decrease inflammation. This is important for premature babies because they are at a greater risk for getting diseases related to inflammation, especially in their lungs, eyes and intestines. Since DHA is so important for normal growth, you will find DHA naturally in breast milk and it is now added to infant formula. But the amount in breast milk and infant formula is about half of what your infant should expect to get in the womb (about 13-29mg per day in breast milk vs. 50-75mg per day in the womb). Very premature babies are at an even greater disadvantage because they cannot always eat very much right away and that is the only way they can get essential fatty acids in their body. This means premature babies are getting less DHA than they would in the womb and then the "DHA gap" continues for a longer period of time. This gap also comes at a time when their brain is growing most rapidly and their bodies need it the most. This trial is designed to see if giving DHA, even before the baby can take food orally, will raise his/her DHA blood levels to those of normal term babies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117
- Sanford Health USD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Preterm infants between 24 and 33 6/7 weeks gestation
- must be less than or equal to 1 week of age
Exclusion Criteria:
- infants who are considered by the medical team to be non-viable
- infants with multiple or severe congenital anomalies such as gastroschisis, congenital chylothorax or other illnesses that do not allow a feeding tube to be placed or utilized at 7 days of age.
- term infants: who are born to mothers with diabetes or are small for gestational age (SGA-less than the 10th% for adjusted gestational age
- All families consented for this study will need to be able to read and write English
- Mother must be 18 years of age or older
- Taking Omegaven
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: DHA oil
DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
|
Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
|
Placebo Comparator: (MCT) control oil
MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
|
Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days to Reach Full Enteral Feedings and Days on Study Oil.
Time Frame: From enrollment until the infant reaches full feed or is discharged from the NICU, whichever comes first, assessed up to 50 days.
|
This study was designed to determine feasibility and tolerability of enteral DHA supplementation, but was not intended to determine the effects of DHA on health related outcomes.
Tolerability was measured by days to reach full enteral feedings, days on study oil, GA at completion of the study and postnatal growth.
The days to reach full enteral feedings was defined as enteral intake of 100kcal/kg/d.
Safety and tolerability was closely monitored under the oversight of an independent DSMB.
|
From enrollment until the infant reaches full feed or is discharged from the NICU, whichever comes first, assessed up to 50 days.
|
Feasibility and Tolerability of Daily Enteral DHA Oil - Weight Change
Time Frame: 30 days from birth
|
A linear mixed model was used to explore weight over time.
|
30 days from birth
|
Long Chain Polyunsaturated Fatty Acid (LCPUFA) Levels - Docosahexaenoic Acid (DHA) Levels in Whole Blood
Time Frame: At baseline (enrollment, < 1 week of age), full feedings, discharge
|
Linear mixed models were also used to examine the association between each FA of interest and treatment group over time.
Since only three time points were available for FA measurement, only a random intercept was included in the models.
For these models, the random effect for multiples was again found to be not needed and removed.
Primary outcome variables for this analysis included LNA, ALA, ARA and DHA.
Only early/late preterm status was included in the model as a covariate since this was a stratification variable.
Continuous dependent variables were transformed using the natural logarithm as needed to meet the assumptions of the regression model (this included LNA and ALA).
|
At baseline (enrollment, < 1 week of age), full feedings, discharge
|
Feasibility and Tolerability of Daily Enteral DHA Oil - Length Change
Time Frame: 30 days from birth
|
A linear mixed model was used to explore length over time.
|
30 days from birth
|
Feasibility and Tolerability of Daily Enteral DHA Oil - Head Circumference
Time Frame: 30 days from birth
|
A linear mixed model was used to explore head circumference over time.
|
30 days from birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LCPUFA Levels - Arachidonic Acid (ARA) in Whole Blood
Time Frame: At baseline (enrollment, <1 week of age), full feedings and discharge
|
Linear mixed models were also used to examine the association between each FA of interest and treatment group over time.
Since only three time points were available for FA measurement, only a random intercept was included in the models.
For these models, the random effect for multiples was again found to be not needed and removed.
Primary outcome variables for this analysis included LNA, ALA, ARA and DHA.
Only early/late preterm status was included in the model as a covariate since this was a stratification variable.
Continuous dependent variables were transformed using the natural logarithm as needed to meet the assumptions of the regression model (this included LNA and ALA).
|
At baseline (enrollment, <1 week of age), full feedings and discharge
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LCPUFA Levels - Alpha-linolenic Acid (ALA) in Whole Blood
Time Frame: Baseline (<1 week of age), full enteral feedings and discharge
|
Linear mixed models were also used to examine the association between each FA of interest and treatment group over time.
Since only three time points were available for FA measurement, only a random intercept was included in the models.
For these models, the random effect for multiples was again found to be not needed and removed.
Primary outcome variables for this analysis included LNA, ALA, ARA and DHA.
Only early/late preterm status was included in the model as a covariate since this was a stratification variable.
Continuous dependent variables were transformed using the natural logarithm as needed to meet the assumptions of the regression model (this included LNA and ALA).
|
Baseline (<1 week of age), full enteral feedings and discharge
|
LCPUFA Levels - Linoleic Acid (LNA)
Time Frame: Baseline, full feedings and discharge
|
Linear mixed models were also used to examine the association between each FA of interest and treatment group over time.
Since only three time points were available for FA measurement, only a random intercept was included in the models.
For these models, the random effect for multiples was again found to be not needed and removed.
Primary outcome variables for this analysis included LNA, ALA, ARA and DHA.
Only early/late preterm status was included in the model as a covariate since this was a stratification variable.
Continuous dependent variables were transformed using the natural logarithm as needed to meet the assumptions of the regression model (this included LNA and ALA).
|
Baseline, full feedings and discharge
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michelle L Baack, MD, Sanford Health
Publications and helpful links
General Publications
- Baack ML, Puumala SE, Messier SE, Pritchett DK, Harris WS. Daily Enteral DHA Supplementation Alleviates Deficiency in Premature Infants. Lipids. 2016 Apr;51(4):423-33. doi: 10.1007/s11745-016-4130-4. Epub 2016 Feb 4.
- Baack ML, Puumala SE, Messier SE, Pritchett DK, Harris WS. What is the relationship between gestational age and docosahexaenoic acid (DHA) and arachidonic acid (ARA) levels? Prostaglandins Leukot Essent Fatty Acids. 2015 Sep;100:5-11. doi: 10.1016/j.plefa.2015.05.003. Epub 2015 Jun 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DHA Gap
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prematurity
-
Stanford UniversityMedtronic - MITGCompletedIntraventricular Hemorrhage of Prematurity | Complications of PrematurityUnited States
-
Universidade Federal do MaranhãoConselho Nacional de Desenvolvimento Científico e TecnológicoUnknown
-
University of WashingtonNational Institute of Neurological Disorders and Stroke (NINDS)CompletedExtreme PrematurityUnited States
-
University of Alabama at BirminghamRecruitingPrematurity; ExtremeUnited States
-
Stockholm UniversityKarolinska Institutet; Region Stockholm; Centrum för kompetensutveckling inom... and other collaboratorsActive, not recruiting
-
Guilherme Sant'Anna, MDCompleted
-
University of Kansas Medical CenterCompletedComplication of PrematurityUnited States
-
Zekai Tahir Burak Women's Health Research and Education...UnknownPrematurity of FetusTurkey
-
Mansoura University Children HospitalCompletedPrematurity, Mechanical VentilationEgypt
Clinical Trials on DHA oil
-
National Science Council, TaiwanCompletedMajor Depressive DisorderTaiwan
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedProteomics | Lipoprotein Metabolism | PCSK9United States
-
University of New MexicoNational Center for Research Resources (NCRR)TerminatedPregnancy | Randomized Clinical Trial | Docosahexaenoic AcidUnited States
-
University of CincinnatiCompletedSchizophrenia | Fatty Acid DeficiencyUnited States
-
Indonesian Nutrition AssociationRecruitingHealthy ChildrenIndonesia
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)CompletedType 2 Diabetes Mellitus | ThrombosisUnited States
-
Midwest Center for Metabolic and Cardiovascular...NaturmegaCompleted
-
CHU de Quebec-Universite LavalCanadian Institutes of Health Research (CIHR); Laval UniversityActive, not recruitingChild Development | Bronchopulmonary Dysplasia | Neonatal and Perinatal ConditionsCanada
-
Université Catholique de LouvainCompleted
-
Mead Johnson NutritionChinese Academy of Sciences; International Peace Maternity and Child Health...WithdrawnAtopic DermatitisChina